TR201908663T4 - İmmünoglobülin tek değişken alanlarının kararlı formülasyonları ve bunların kullanımları. - Google Patents
İmmünoglobülin tek değişken alanlarının kararlı formülasyonları ve bunların kullanımları. Download PDFInfo
- Publication number
- TR201908663T4 TR201908663T4 TR2019/08663T TR201908663T TR201908663T4 TR 201908663 T4 TR201908663 T4 TR 201908663T4 TR 2019/08663 T TR2019/08663 T TR 2019/08663T TR 201908663 T TR201908663 T TR 201908663T TR 201908663 T4 TR201908663 T4 TR 201908663T4
- Authority
- TR
- Turkey
- Prior art keywords
- formulations
- stable
- immunoglobulin
- univariate
- variable domains
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 108060003951 Immunoglobulin Proteins 0.000 title abstract 3
- 102000018358 immunoglobulin Human genes 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 238000013019 agitation Methods 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361824523P | 2013-05-17 | 2013-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201908663T4 true TR201908663T4 (tr) | 2019-07-22 |
Family
ID=49304267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/08663T TR201908663T4 (tr) | 2013-05-17 | 2014-05-16 | İmmünoglobülin tek değişken alanlarının kararlı formülasyonları ve bunların kullanımları. |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10035862B2 (enExample) |
| EP (2) | EP2996720B1 (enExample) |
| JP (2) | JP6433986B2 (enExample) |
| KR (1) | KR102166399B1 (enExample) |
| CN (3) | CN110063935B (enExample) |
| AU (3) | AU2014267222B2 (enExample) |
| BR (1) | BR112015028411B1 (enExample) |
| CA (1) | CA2912670A1 (enExample) |
| CY (1) | CY1122090T1 (enExample) |
| DK (1) | DK2996720T3 (enExample) |
| ES (2) | ES2895150T3 (enExample) |
| HR (1) | HRP20190954T1 (enExample) |
| HU (1) | HUE044392T2 (enExample) |
| LT (1) | LT2996720T (enExample) |
| MX (2) | MX387527B (enExample) |
| NL (1) | NL1040254C2 (enExample) |
| PH (1) | PH12015502591A1 (enExample) |
| PL (2) | PL3511018T3 (enExample) |
| PT (2) | PT2996720T (enExample) |
| RS (1) | RS58857B1 (enExample) |
| RU (1) | RU2671977C2 (enExample) |
| SI (1) | SI2996720T1 (enExample) |
| SM (1) | SMT201900359T1 (enExample) |
| TR (1) | TR201908663T4 (enExample) |
| WO (1) | WO2014184352A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL1040254C2 (en) * | 2013-05-17 | 2014-11-24 | Ablynx Nv | Stable formulations of immunoglobulin single variable domains and uses thereof. |
| PT3233910T (pt) | 2014-12-19 | 2020-03-17 | Ablynx Nv | Dímeros de nanocorpos ligados a cisteína |
| CN105833255A (zh) * | 2016-03-23 | 2016-08-10 | 兆科药业（合肥）有限公司 | 抗血小板溶栓素在制备治疗血栓性血小板减少性紫癜的药物中的应用 |
| GB201612043D0 (en) | 2016-07-11 | 2016-08-24 | Crescendo Biologics Ltd | Composition for treatment of disorders |
| EP3534963B1 (en) * | 2016-11-02 | 2024-04-17 | Polaris Group | Formulations of pegylated arginine deiminase |
| AU2019217584B2 (en) | 2018-02-06 | 2025-08-14 | Ablynx Nv | Methods of treating initial episode of TTP with immunoglobulin single variable domains |
| MX2020013734A (es) | 2018-07-03 | 2021-05-27 | Fennec Pharmaceuticals Inc | Formulaciones de tiosulfato de sodio anhidro. |
| JP7653352B2 (ja) * | 2018-09-05 | 2025-03-28 | エクスプレステック、リミテッド、ライアビリティ、カンパニー | 免疫グロブリンａ製剤 |
| CN112839683B (zh) * | 2018-10-10 | 2023-11-14 | 安斯泰来制药株式会社 | 含有标记部-抗人抗体Fab片段复合物的药物组合物 |
| CN110564841A (zh) * | 2019-09-19 | 2019-12-13 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 脑缺血相关基因作为缺血性卒中行为学特征分析的生物标记的应用 |
| CN110624105B (zh) * | 2019-09-24 | 2021-06-11 | 苏州大学 | 血管性血友病因子的结构敏感多肽抗原的序列 |
| JP7502861B2 (ja) * | 2019-12-27 | 2024-06-19 | 旭化成株式会社 | 標的物質と両親媒性高分子との複合体の形成反応の反応温度の評価方法 |
| CN113908254B (zh) * | 2021-10-19 | 2024-05-28 | 山西锦波生物医药股份有限公司 | 一种干粉吸入剂及其制备方法和用途 |
| CN115850493B (zh) * | 2022-11-08 | 2024-03-12 | 江苏耀海生物制药有限公司 | 一种二价纳米抗体Cablivi的分离纯化方法 |
| WO2025240928A1 (en) * | 2024-05-16 | 2025-11-20 | Vega Therapeutics, Inc. | Treatment of von willebrand disease |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE452975T1 (de) | 1992-08-21 | 2010-01-15 | Univ Bruxelles | Immunoglobuline ohne leichte ketten |
| ATE204325T1 (de) | 1993-04-29 | 2001-09-15 | Unilever Nv | Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae |
| FR2708622B1 (fr) | 1993-08-02 | 1997-04-18 | Raymond Hamers | Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides. |
| CA2190502A1 (en) | 1994-05-18 | 1995-11-23 | Robert M. Platz | Methods and compositions for the dry powder formulation of interferons |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| DE69738166T2 (de) | 1996-06-27 | 2008-06-19 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | Antikörpermoleküle, die spezifisch mit dem aktiven Zentrum oder dem aktiven Spalt eines Zielmoleküls interagieren |
| US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
| EP1027439B1 (en) | 1997-10-27 | 2010-03-17 | Bac Ip B.V. | Multivalent antigen-binding proteins |
| AU3596599A (en) | 1998-01-26 | 1999-08-09 | Unilever Plc | Method for producing antibody fragments |
| EP0967284A1 (en) | 1998-05-28 | 1999-12-29 | Pfizer Limited | Phosphodiesterases |
| AU3041100A (en) | 1999-01-05 | 2000-07-24 | Unilever Plc | Binding of antibody fragments to solid supports |
| ATE276359T1 (de) | 1999-01-19 | 2004-10-15 | Unilever Nv | Verfahren zur herstellung von antikörperfragmenten |
| WO2000046383A2 (en) | 1999-02-05 | 2000-08-10 | Rijksuniversiteit Leiden | Method of modulating metabolite biosynthesis in recombinant cells |
| CA2367955C (en) | 1999-03-15 | 2009-05-19 | University Of British Columbia | Abc1 polypeptide and methods and reagents for modulating cholesterol levels |
| CN1252264C (zh) | 1999-04-22 | 2006-04-19 | 荷兰联合利华有限公司 | 利用单价抗原－结合蛋白抑制病毒感染 |
| BR0011753A (pt) | 1999-06-18 | 2002-04-30 | Cv Therapeutics Inc | Composições e métodos para aumentar o efluxo de colesterol e elevar o hdl utilizando a proteìna abc1 transportadora do cassete de ligação de atp |
| EP1198572A2 (en) | 1999-08-02 | 2002-04-24 | Keygene N.V. | Method for generating cgmmv resistant plants, genetic constructs, and obtained cgmmv-resistant plants |
| GB9922124D0 (en) | 1999-09-17 | 1999-11-17 | Pfizer Ltd | Phosphodiesterase enzymes |
| US6479280B1 (en) | 1999-09-24 | 2002-11-12 | Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw | Recombinant phages capable of entering host cells via specific interaction with an artificial receptor |
| DE19955408A1 (de) | 1999-11-18 | 2001-05-23 | Bayer Ag | GABA-B-Rezeptoren |
| WO2001040310A2 (en) | 1999-11-29 | 2001-06-07 | Unilever Plc | Immobilisation of proteins using a polypeptide segment |
| EP1233987B1 (en) | 1999-11-29 | 2009-08-19 | Bac Ip B.V. | Immobilized single domain antigen-binding molecules |
| DE60138333D1 (de) | 2000-03-14 | 2009-05-28 | Unilever Nv | Variabele Domänen der schweren Kette eines Antikörpers gegen menschliche Ernährungslipasen und deren Verwendungen |
| AU2001268855A1 (en) | 2000-05-26 | 2001-12-03 | National Research Council Of Canada | Single-domain antigen-binding antibody fragments derived from llama antibodies |
| DK1360207T3 (da) | 2000-12-13 | 2011-09-05 | Bac Ip B V | Proteinarray af variable domæner af tunge immunoglobulinkæder fra kameler |
| DK1419179T3 (da) | 2001-08-10 | 2010-06-21 | Univ Aberdeen | Antigenbindingsdomæner fra fisk |
| US7371849B2 (en) | 2001-09-13 | 2008-05-13 | Institute For Antibodies Co., Ltd. | Methods of constructing camel antibody libraries |
| US6723359B2 (en) | 2001-10-18 | 2004-04-20 | Firmenich Sa | Spray-dried compositions and method for their preparation |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| EP1456410A2 (en) | 2001-12-11 | 2004-09-15 | AlgoNomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
| WO2003054016A2 (en) | 2001-12-21 | 2003-07-03 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Method for cloning of variable domain sequences |
| JP2005517674A (ja) | 2002-01-03 | 2005-06-16 | フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー | 腫瘍の処置に有用な新規免疫コンジュゲート |
| GB0202633D0 (en) * | 2002-02-05 | 2002-03-20 | Delta Biotechnology Ltd | Stabilization of protein preparations |
| ATE512364T1 (de) | 2002-08-07 | 2011-06-15 | Ablynx Nv | Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha |
| JP2006512910A (ja) | 2002-10-23 | 2006-04-20 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | Ａ３４およびａ３３様３ｄｎａ、タンパク質、それらに対する抗体、ならびに同一物を使用した治療方法 |
| US20060228355A1 (en) | 2003-11-07 | 2006-10-12 | Toon Laeremans | Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor |
| EP1558646A2 (en) | 2002-11-08 | 2005-08-03 | Ablynx N.V. | Single domain antibodies directed against interferon- gamma and uses thereof |
| NZ540196A (en) | 2002-11-08 | 2008-09-26 | Ablynx Nv | Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders |
| US9028816B2 (en) | 2003-01-10 | 2015-05-12 | Ablynx N.V. | Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor |
| BRPI0518151A2 (pt) | 2004-10-13 | 2009-06-16 | Ablynx Nv | polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo |
| AU2006205900B8 (en) | 2005-01-14 | 2012-04-05 | Ablynx N.V. | Methods and assays for distinguishing between different forms of diseases and disorders characterized by thrombocytopenia and/or by spontaneous interaction between Von Willebrand Factor (vWF) and platelets |
| EP1844073A1 (en) | 2005-01-31 | 2007-10-17 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
| US8188223B2 (en) | 2005-05-18 | 2012-05-29 | Ablynx N.V. | Serum albumin binding proteins |
| ES2694247T3 (es) | 2005-05-20 | 2018-12-19 | Ablynx N.V. | NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación |
| CN101262885B (zh) * | 2005-06-10 | 2015-04-01 | 中外制药株式会社 | 含有sc(Fv)2的药物组合物 |
| CA2644405A1 (en) | 2006-03-13 | 2007-09-20 | Ablynx N.V. | Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| EP2097449A1 (en) | 2006-12-05 | 2009-09-09 | Ablynx N.V. | Peptides capable of binding to serum proteins |
| UA96473C2 (ru) * | 2007-03-22 | 2011-11-10 | Имклоун Ллк | Жидкая стойкая композиция, которая содержит антитело imc-а12 |
| JP5784907B2 (ja) * | 2007-12-28 | 2015-09-24 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | 組換え型ｖｗｆ製剤 |
| WO2009090189A1 (en) * | 2008-01-15 | 2009-07-23 | Abbott Gmbh & Co.Kg | Powdered protein compositions and methods of making same |
| AU2009227055A1 (en) * | 2008-03-21 | 2009-09-24 | Ablynx Nv | Von Willebrand Factor specific binders and methods of use therefor |
| JP2011516603A (ja) | 2008-04-17 | 2011-05-26 | アブリンクス エン．ヴェー． | 血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド |
| AR074054A1 (es) * | 2008-10-21 | 2010-12-22 | Baxter Healthcare Sa | Formulaciones farmaceuticas de factor de von willebrand recombinante liofilizado |
| EP4104821A1 (en) * | 2008-10-29 | 2022-12-21 | Ablynx N.V. | Formulations of single domain antigen binding molecules |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| WO2011067160A1 (en) | 2009-12-01 | 2011-06-09 | Ablynx Nv | Von willebrand factor specific binding agents and uses thereof |
| CA2788993A1 (en) | 2010-02-05 | 2011-08-11 | Ablynx N.V. | Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same |
| CN102753148B (zh) * | 2010-02-11 | 2018-01-26 | 埃博灵克斯股份有限公司 | 用于制备气雾剂的方法和组合物 |
| US20120225072A1 (en) * | 2011-03-02 | 2012-09-06 | Ablynx N.V. | Stable formulations of immunoglobulin single variable domains and uses thereof |
| NL1040254C2 (en) * | 2013-05-17 | 2014-11-24 | Ablynx Nv | Stable formulations of immunoglobulin single variable domains and uses thereof. |
-
2013
- 2013-06-14 NL NL1040254A patent/NL1040254C2/en active
-
2014
- 2014-05-16 KR KR1020157035523A patent/KR102166399B1/ko active Active
- 2014-05-16 SI SI201431229T patent/SI2996720T1/sl unknown
- 2014-05-16 PT PT14727433T patent/PT2996720T/pt unknown
- 2014-05-16 WO PCT/EP2014/060107 patent/WO2014184352A1/en not_active Ceased
- 2014-05-16 SM SM20190359T patent/SMT201900359T1/it unknown
- 2014-05-16 DK DK14727433.6T patent/DK2996720T3/da active
- 2014-05-16 EP EP14727433.6A patent/EP2996720B1/en active Active
- 2014-05-16 EP EP19157147.0A patent/EP3511018B1/en active Active
- 2014-05-16 BR BR112015028411-6A patent/BR112015028411B1/pt active IP Right Grant
- 2014-05-16 PL PL19157147T patent/PL3511018T3/pl unknown
- 2014-05-16 HU HUE14727433 patent/HUE044392T2/hu unknown
- 2014-05-16 AU AU2014267222A patent/AU2014267222B2/en active Active
- 2014-05-16 PL PL14727433T patent/PL2996720T3/pl unknown
- 2014-05-16 PT PT191571470T patent/PT3511018T/pt unknown
- 2014-05-16 TR TR2019/08663T patent/TR201908663T4/tr unknown
- 2014-05-16 HR HRP20190954TT patent/HRP20190954T1/hr unknown
- 2014-05-16 ES ES19157147T patent/ES2895150T3/es active Active
- 2014-05-16 JP JP2016513387A patent/JP6433986B2/ja active Active
- 2014-05-16 CN CN201811423557.0A patent/CN110063935B/zh active Active
- 2014-05-16 RU RU2015154214A patent/RU2671977C2/ru active
- 2014-05-16 CN CN201811422890.XA patent/CN110037983A/zh active Pending
- 2014-05-16 MX MX2019005269A patent/MX387527B/es unknown
- 2014-05-16 LT LTEP14727433.6T patent/LT2996720T/lt unknown
- 2014-05-16 CA CA2912670A patent/CA2912670A1/en not_active Abandoned
- 2014-05-16 ES ES14727433T patent/ES2731922T3/es active Active
- 2014-05-16 MX MX2015015722A patent/MX364664B/es active IP Right Grant
- 2014-05-16 US US14/891,441 patent/US10035862B2/en active Active
- 2014-05-16 CN CN201480034630.9A patent/CN105339003B/zh active Active
- 2014-05-16 RS RS20190694A patent/RS58857B1/sr unknown
-
2015
- 2015-11-16 PH PH12015502591A patent/PH12015502591A1/en unknown
-
2018
- 2018-06-14 US US16/008,103 patent/US20190010249A1/en active Pending
- 2018-11-07 JP JP2018209611A patent/JP6952019B2/ja active Active
-
2019
- 2019-02-25 AU AU2019201307A patent/AU2019201307B2/en active Active
- 2019-06-26 CY CY20191100669T patent/CY1122090T1/el unknown
-
2021
- 2021-01-05 AU AU2021200035A patent/AU2021200035A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201908663T4 (tr) | İmmünoglobülin tek değişken alanlarının kararlı formülasyonları ve bunların kullanımları. | |
| CY1125016T1 (el) | Διαμορφωτες υποδοχεα πιπεριδινης cxcr7 | |
| CY1120507T1 (el) | Συνεργιστικη ενισχυση της διανομης νουκλεϊκων οξεων μεσω συμμειγμενων σκευασματων | |
| MX366854B (es) | Polipeptidos que continen fc aglicosilados. | |
| BR112016000937A8 (pt) | formulações farmacêuticas de pó seco, método para a fabricação de uma formulação de pó seco e uso de uma formulação farmacêutica de pó seco | |
| CY1120622T1 (el) | Μεθοδοι και συνθεσεις για επαγωγη μιας ανοσιακης αποκρισης ως προς egfrviii | |
| MX381011B (es) | Complejo del factor viii con xten y proteína del factor von willebrand, y sus usos. | |
| BR112014000466A2 (pt) | polipeptídeos quiméricos e híbridos fator viii, métodos de uso dos mesmos | |
| CL2008000912A1 (es) | Proteina insecticida hibrida que comprende dos proteinas cry del bacillus thuringiensis (bt) diferentes; molecula de acido nucleico que comprende dicha proteina; casete de expresion, vector recombinante que comprenden el acido nucleico; celula transg | |
| BR112013006679A2 (pt) | imunoglobulinas carreadoras e seus usos | |
| BR112013000650A8 (pt) | poliptídeos de fator ix e métodos de uso dos mesmos. | |
| CY1113869T1 (el) | Λυοφιλιωμενα σκευασματα ανασυνδυασμενου vwf | |
| CY1121829T1 (el) | Κατιονικα πολυμερη που εχουν τη βαση τους στο γλυκογονο | |
| BR112016002614A8 (pt) | Imunocitoquina, ácido nucleico, vetor, célula hospedeira e composição farmacêutica | |
| CY1121466T1 (el) | Αντισωματα εναντι προσδεματων υποδοχεα β1 βραδυκινινης | |
| NO20085362L (no) | Hoyaffinitets humane og humaniserte anti-alfa5 beta1-integrin funksjonsblokkerende antistoffer med redusert immunogenisitet | |
| BR112019011065A2 (pt) | métodos para determinação da dosagem de células t car | |
| BR112013004436A2 (pt) | composições e usos de materiais com atividade microbicida alta e toxicidade baixa | |
| WO2015058173A8 (en) | Stable solid units and methods of making the same | |
| SV2016005264A (es) | Proteínas de fusión tatk-cdkl5, composiciones, formulaciones y uso de estas | |
| BR112018077225A2 (pt) | proteínas de fusão tatk-cdkl5, composições, formulações e uso das mesmas | |
| EA201591609A1 (ru) | Варианты альфа-амилазы | |
| WO2014144768A3 (en) | Bh4 stabilized peptides and uses thereof | |
| TR201901717T4 (tr) | CMAP27 ye dayalı antimikrobiyal peptidler. | |
| MX388753B (es) | Complejos no covalentes basados en albúmina y métodos de uso de los mismos. |